429 related articles for article (PubMed ID: 29475919)
1. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
2. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
4. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Lee H; Hodi FS; Giobbie-Hurder A; Ott PA; Buchbinder EI; Haq R; Tolaney S; Barroso-Sousa R; Zhang K; Donahue H; Davis M; Gargano ME; Kelley KM; Carroll RS; Kaiser UB; Min L
Cancer Immunol Res; 2017 Dec; 5(12):1133-1140. PubMed ID: 29079654
[TBL] [Abstract][Full Text] [Related]
6. [Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].
Inaba H; Ariyasu H; Kurimoto C; Iwakura H; Akamizu T
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1031-1035. PubMed ID: 30042266
[TBL] [Abstract][Full Text] [Related]
7. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
10. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
[TBL] [Abstract][Full Text] [Related]
11. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
13. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
Trinh B; Sanchez GO; Herzig P; Läubli H
J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
[TBL] [Abstract][Full Text] [Related]
14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
15. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
16. An unusual case of hypopituitarism and transient thyrotoxicosis following asymptomatic pituitary apoplexy.
Yoshida M; Murakami M; Ueda H; Miyata M; Takahashi N; Oiso Y
Neuro Endocrinol Lett; 2014; 35(5):342-6. PubMed ID: 25275254
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
19. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
20. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]